Moreover, the 36-month beta value for MRSN is 0.82. Analysts have varying opinions on the stock, with 8 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for MRSN is 96.84M and currently, short sellers hold a 15.56% of that float. On July 09, 2025, MRSN’s average trading volume was 2.76M shares.
MRSN) stock’s latest price update
The stock price of Mersana Therapeutics Inc (NASDAQ: MRSN) has surged by 7.46% when compared to previous closing price of $0.3, but the company has seen a 10.47% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-02 that CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced additional interim Phase 1 clinical data for emiltatug ledadotin (Emi-Le; XMT-1660), the company’s B7-H4-directed Dolasynthen ADC. These data are being presented in an oral session today at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago, Illinois.
MRSN’s Market Performance
Mersana Therapeutics Inc (MRSN) has seen a 10.47% rise in stock performance for the week, with a -11.21% decline in the past month and a 7.96% surge in the past quarter. The volatility ratio for the week is 7.38%, and the volatility levels for the past 30 days are at 9.06% for MRSN. The simple moving average for the last 20 days is -3.66% for MRSN stock, with a simple moving average of -68.92% for the last 200 days.
Analysts’ Opinion of MRSN
Citigroup, on the other hand, stated in their research note that they expect to see MRSN reach a price target of $5. The rating they have provided for MRSN stocks is “Buy” according to the report published on November 15th, 2024.
JP Morgan gave a rating of “Neutral” to MRSN, setting the target price at $5 in the report published on March 19th of the previous year.
MRSN Trading at -7.55% from the 50-Day Moving Average
After a stumble in the market that brought MRSN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.45% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRSN starting from Mandelia Ashish, who sale 3,554 shares at the price of $0.58 back on Jan 16 ’25. After this action, Mandelia Ashish now owns 57,519 shares of Mersana Therapeutics Inc, valued at $2,061 using the latest closing price.
Protopapas Anna, the Director of Mersana Therapeutics Inc, sale 8,637 shares at $0.58 during a trade that took place back on Jan 16 ’25, which means that Protopapas Anna is holding 168,041 shares at $5,009 based on the most recent closing price.
Stock Fundamentals for MRSN
Current profitability levels for the company are sitting at:
- -2.26 for the present operating margin
- 1.0 for the gross margin
The net margin for Mersana Therapeutics Inc stands at -2.18. The total capital return value is set at -1.41. Equity return is now at value -505.14, with -47.62 for asset returns.
Based on Mersana Therapeutics Inc (MRSN), the company’s capital structure generated -1.18 points at debt to capital in total, while cash flow to debt ratio is standing at -4.72. The debt to equity ratio resting at -0.54. The interest coverage ratio of the stock is -21.07.
Currently, EBITDA for the company is -63.27 million with net debt to EBITDA at 1.25. When we switch over and look at the enterprise to sales, we see a ratio of -1.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.83.
Conclusion
To wrap up, the performance of Mersana Therapeutics Inc (MRSN) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
